Cell-based therapies for diabetic retinopathy

Lynn C. Shaw, Matthew B. Neu, Maria B. Grant

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Autologous endothelial progenitor cell (EPC) populations represent a novel treatment for therapeutic revascularization and vascular repair for diabetic patients with complications including diabetic retinopathy. Current therapies are applicable to late-stage disease and carry significant side effects, whereas cell-based therapy may provide an alternative by repairing areas of vasodegeneration and reversing ischemia. However, EPCs from diabetic patients with vascular complications are dysfunctional. Moreover, the diabetic environment poses its own challenges and complicates the use of autologous EPCs. Before EPCs become the ideal "cell therapy," the optimal EPC must be determined, any functional dysfunction must be corrected prior to use, and the diabetic milieu will require modification to accept the EPCs. This review describes the rationale for harnessing the vascular reparative properties of EPCs with emphasis on the molecular and phenotypic nature of healthy EPCs, how diabetes alters them, and novel strategies to improve dysfunctional EPCs.

Original languageEnglish (US)
Pages (from-to)265-274
Number of pages10
JournalCurrent Diabetes Reports
Volume11
Issue number4
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Cell- and Tissue-Based Therapy
Blood Vessels
erucylphosphocholine
Therapeutics
Ischemia
Population

Keywords

  • Circulating angiogenic cells
  • Circulating endothelial cells
  • Diabetes
  • Diabetic retinopathy
  • Embryonic stem cells
  • Endothelial progenitor cell
  • Outgrowth endothelial cell
  • Renin-angiotensin-aldosterone system
  • Stem cell therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Cell-based therapies for diabetic retinopathy. / Shaw, Lynn C.; Neu, Matthew B.; Grant, Maria B.

In: Current Diabetes Reports, Vol. 11, No. 4, 08.2011, p. 265-274.

Research output: Contribution to journalArticle

Shaw, Lynn C. ; Neu, Matthew B. ; Grant, Maria B. / Cell-based therapies for diabetic retinopathy. In: Current Diabetes Reports. 2011 ; Vol. 11, No. 4. pp. 265-274.
@article{eec018f3ac8949f7aa4c1b01598ee14c,
title = "Cell-based therapies for diabetic retinopathy",
abstract = "Autologous endothelial progenitor cell (EPC) populations represent a novel treatment for therapeutic revascularization and vascular repair for diabetic patients with complications including diabetic retinopathy. Current therapies are applicable to late-stage disease and carry significant side effects, whereas cell-based therapy may provide an alternative by repairing areas of vasodegeneration and reversing ischemia. However, EPCs from diabetic patients with vascular complications are dysfunctional. Moreover, the diabetic environment poses its own challenges and complicates the use of autologous EPCs. Before EPCs become the ideal {"}cell therapy,{"} the optimal EPC must be determined, any functional dysfunction must be corrected prior to use, and the diabetic milieu will require modification to accept the EPCs. This review describes the rationale for harnessing the vascular reparative properties of EPCs with emphasis on the molecular and phenotypic nature of healthy EPCs, how diabetes alters them, and novel strategies to improve dysfunctional EPCs.",
keywords = "Circulating angiogenic cells, Circulating endothelial cells, Diabetes, Diabetic retinopathy, Embryonic stem cells, Endothelial progenitor cell, Outgrowth endothelial cell, Renin-angiotensin-aldosterone system, Stem cell therapy",
author = "Shaw, {Lynn C.} and Neu, {Matthew B.} and Grant, {Maria B.}",
year = "2011",
month = "8",
doi = "10.1007/s11892-011-0197-8",
language = "English (US)",
volume = "11",
pages = "265--274",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Cell-based therapies for diabetic retinopathy

AU - Shaw, Lynn C.

AU - Neu, Matthew B.

AU - Grant, Maria B.

PY - 2011/8

Y1 - 2011/8

N2 - Autologous endothelial progenitor cell (EPC) populations represent a novel treatment for therapeutic revascularization and vascular repair for diabetic patients with complications including diabetic retinopathy. Current therapies are applicable to late-stage disease and carry significant side effects, whereas cell-based therapy may provide an alternative by repairing areas of vasodegeneration and reversing ischemia. However, EPCs from diabetic patients with vascular complications are dysfunctional. Moreover, the diabetic environment poses its own challenges and complicates the use of autologous EPCs. Before EPCs become the ideal "cell therapy," the optimal EPC must be determined, any functional dysfunction must be corrected prior to use, and the diabetic milieu will require modification to accept the EPCs. This review describes the rationale for harnessing the vascular reparative properties of EPCs with emphasis on the molecular and phenotypic nature of healthy EPCs, how diabetes alters them, and novel strategies to improve dysfunctional EPCs.

AB - Autologous endothelial progenitor cell (EPC) populations represent a novel treatment for therapeutic revascularization and vascular repair for diabetic patients with complications including diabetic retinopathy. Current therapies are applicable to late-stage disease and carry significant side effects, whereas cell-based therapy may provide an alternative by repairing areas of vasodegeneration and reversing ischemia. However, EPCs from diabetic patients with vascular complications are dysfunctional. Moreover, the diabetic environment poses its own challenges and complicates the use of autologous EPCs. Before EPCs become the ideal "cell therapy," the optimal EPC must be determined, any functional dysfunction must be corrected prior to use, and the diabetic milieu will require modification to accept the EPCs. This review describes the rationale for harnessing the vascular reparative properties of EPCs with emphasis on the molecular and phenotypic nature of healthy EPCs, how diabetes alters them, and novel strategies to improve dysfunctional EPCs.

KW - Circulating angiogenic cells

KW - Circulating endothelial cells

KW - Diabetes

KW - Diabetic retinopathy

KW - Embryonic stem cells

KW - Endothelial progenitor cell

KW - Outgrowth endothelial cell

KW - Renin-angiotensin-aldosterone system

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=80051600747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051600747&partnerID=8YFLogxK

U2 - 10.1007/s11892-011-0197-8

DO - 10.1007/s11892-011-0197-8

M3 - Article

C2 - 21611766

AN - SCOPUS:80051600747

VL - 11

SP - 265

EP - 274

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 4

ER -